Cerebral circulatory and cardiac effects of vinpocetine and its metabolite, apovincaminic acid, in anesthetized dogs.
Cerebral circulatory and cardiac actions of vinpocetine and its metabolite, apovincaminic acid (AVA), were studied in anesthetized dogs. Injections of vinpocetine (0.03 to 1.0 mg/dog) into the vertebral or coronary artery produced dose-dependent increases in the blood flow of each artery. The action was more prominent in the vertebral than in the coronary artery. Intravenous bolus injections of vinpocetine (0.3 and 1.0 mg/kg) transiently increased vertebral flow and superior sagittal sinus flow velocity in a dose-dependent manner. Femoral flow was slightly increased with a fall in diastolic pressure. AVA (1.0 to 5.0 mg/kg) did not significantly increase vertebral, but increased femoral flow, which was accompanied by systemic hypotension. A similar trend of actions was noted after i.v. infusion of both agents (0.15 and 0.5 mg/kg/min for 30 min). An i.d. administration of vinpocetine (10 mg/kg) increased vertebral and regional cerebral cortical flows, accompanying with a fall in diastolic blood pressure. Femoral flow was not affected. An i.v. bolus injection of vinpocetine (1, 3 and 10 mg/kg) transiently decreased systemic blood pressure, left ventricular maximum dp/dt and heart rate in a dose-dependent manner. Cardiac output tended to be increased, and total peripheral resistance decreased. Coronary flow was transiently increased at 1 and 3 mg/kg, but tended to be decreased at 10 mg/kg. AVA, in the same dose range, decreased systemic blood pressure and total peripheral resistance, and increased cardiac output and coronary flow in a dose-dependent manner. An i.v. infusion of vinpocetine (0.5 mg/kg/min for 30 min) decreased systemic blood pressure, left ventricular maximum dp/dt, total peripheral resistance and heart rate.(ABSTRACT TRUNCATED AT 250 WORDS)
D000758:Anesthesia; D000818:Animals; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D004285:Dogs; D005260:Female; D006321:Heart / Q000187:drug effects*; D006439:Hemodynamics / Q000187:drug effects; D007269:Injections, Intra-Arterial; D007275:Injections, Intravenous; D007441:Intubation, Gastrointestinal; D008297:Male; D014665:Vasodilator Agents / Q000494:pharmacology*; D014748:Vinca Alkaloids / Q000008:administration & dosage / Q000494:pharmacology*
D014665:Vasodilator Agents; D014748:Vinca Alkaloids; C032858:apovincaminic acid; C013983:vinpocetine